"iDoctor – Medical Blog"

Isothiocyanate exposure, glutathione S-transferase polymorphisms, and colorectal cancer risk.

Am J Clin Nutr. 2009 Dec 30;

Authors: Yang G, Gao YT, Shu XO, Cai Q, Li GL, Li HL, Ji BT, Rothman N, Dyba M, Xiang YB, Chung FL, Chow WH, Zheng W

BACKGROUND: Isothiocyanates, compounds found primarily in cruciferous vegetables, have been shown in laboratory studies to possess anticarcinogenic activity. Glutathione S-transferases (GSTs) are involved in the metabolism and elimination of isothiocyanates; thus, genetic variations in these enzymes may affect in vivo bioavailability and the activity of isothiocyanates. OBJECTIVE: The objective was to prospectively evaluate the association between urinary isothiocyanate concentrations and colorectal cancer risk as well as the potential modifying effect of GST genotypes on the association. DESIGN: A nested case-control study of 322 cases and 1251 controls identified from the Shanghai Women’s Health Study was conducted. RESULTS: Urinary isothiocyanate concentrations were inversely associated with colorectal cancer risk; the inverse association was statistically significant or nearly significant in the GSTM1-null (P for trend = 0.04) and the GSTT1-null (P for trend = 0.07) genotype groups. The strongest inverse association was found among individuals with both the GSTM1-null and the GSTT1-null genotypes, with an adjusted odds ratio of 0.51 (95% CI: 0.27, 0.95), in a comparison of the highest with the lowest tertile of urinary isothiocyanates. No apparent associations between isothiocyanate concentration and colorectal cancer risk were found between individuals who carried either the GSTM1 or GSTT1 gene (P for interaction < 0.05). CONCLUSION: This study suggests that isothiocyanate exposure may reduce the risk of colorectal cancer, and this protective effect may be modified by the GSTM1 and GSTT1 genes.

PMID: 20042523 [PubMed - as supplied by publisher]

This entry was posted on Saturday, January 2nd, 2010 at 3:14 am and is filed under Health news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.